Developing any new drug is a challenge – particularly when it comes to working with proteins, antibodies, viruses and other complex biologics. Identifying the right targets, excluding misleading candidates and eliminating side-effects are all essential concerns that have proved challenging using existing techniques. MeetTheBoss TV’s Ben Thompson caught up with Paul Helbling, Head of Business Development at Dualsystems Biotech, to find out how a new approach is addressing some of those concerns…